Guggenheim Lowers Valneva (NASDAQ:VALN) Price Target to $15.00

Valneva (NASDAQ:VALN) had its price objective dropped by investment analysts at Guggenheim from $17.00 to $15.00 in a research report issued on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim’s price target would indicate a potential upside of 94.55% from the company’s current price.

Separately, HC Wainwright reiterated a “buy” rating and set a $17.00 price objective on shares of Valneva in a research report on Friday.

Valneva Trading Up 7.5 %

Shares of NASDAQ VALN opened at $7.71 on Monday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78. Valneva has a 52-week low of $3.62 and a 52-week high of $9.50. The firm has a 50 day moving average price of $6.34 and a two-hundred day moving average price of $5.58. The stock has a market cap of $626.52 million, a P/E ratio of -59.31 and a beta of 1.93.

Valneva (NASDAQ:VALN) last announced its quarterly earnings results on Thursday, March 20th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.32). Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%. The business had revenue of $56.48 million during the quarter, compared to analyst estimates of $55.64 million. As a group, equities analysts forecast that Valneva will post 0.13 EPS for the current year.

Institutional Investors Weigh In On Valneva

A hedge fund recently bought a new stake in Valneva stock. ABC Arbitrage SA acquired a new stake in Valneva SE (NASDAQ:VALN) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 19,244 shares of the company’s stock, valued at approximately $84,000. 11.39% of the stock is owned by institutional investors and hedge funds.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.